Impact News +++ Implantica presents the third quarter 2025 on October 31 at 15:00 CET (Cision) +++ IMPLANTICA Aktie -3,60%

EISAI Aktie

>EISAI Aktienkurs

26.7 EUR +3.9% (Tradegate)

Ask: 26.9 EUR / 192 Stück

Bid: 26.3 EUR / 194 Stück

Tagesumsatz: 690 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

EISAI Aktie über LYNX handeln

Intraday

1 Jahr

>EISAI Performance

1 Woche: -0,9%

1 Monat: -14,6%

3 Monate: +6,6%

6 Monate: -0,7%

1 Jahr: -17,4%

laufendes Jahr: -3,5%

>EISAI Aktie

Name:

EISAI CO. LTD

Land:

Japan

Sektor:

Gesundheit

ISIN/ Wkn:

JP3160400002 / 855526

Symbol/ Ticker:

EII (Frankfurt)

Kürzel:

FRA:EII, ETR:EII, EII:GR

Index:

Nikkei225

Webseite:

https://www.eisai.com/

Profil:

Eisai Co., Ltd. is a globally recognized pharmaceu..
>Volltext..

Marktkapitalisierung:

7160.17 Mio. EUR

Unternehmenswert:

7034.06 Mio. EUR

Umsatz:

4791.82 Mio. EUR

EBITDA:

558.66 Mio. EUR

Nettogewinn:

300.31 Mio. EUR

Gewinn je Aktie:

1.06 EUR

Schulden:

1425.69 Mio. EUR

Liquide Mittel:

1702.93 Mio. EUR

Operativer Cashflow:

237.45 Mio. EUR

Bargeldquote:

0.69

Umsatzwachstum:

11.14%

Gewinnwachstum:

56.57%

Dividende je Aktie:

0.91 EUR

Dividendenrendite:

3.55%

Dividendenschätzung:

3.55%

Div. Historie:

29.09.25 - 0.455808€
28.03.25 - 0.455808€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

EISAI

Letzte Datenerhebung:

27.10.25

>EISAI Kennzahlen

Aktien/ Unternehmen:

Aktien: 282.12 Mio. St.

Frei handelbar: 85.99%

Leerverk. Aktien: -

Rückkaufquote: 1.8%

Mitarbeiter: 10917

Umsatz/Mitarb.: 0.41 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 12.24%

Bewertung:

KGV: 24.3

KGV lG: 26.98

KUV: 1.59

KBV: 1.47

PEG-Ratio: 0.45

EV/EBITDA: 12.59

Rentabilität:

Bruttomarge: 78.62%

Gewinnmarge: 6.27%

Operative Marge: 6.73%

Managementeffizenz:

Gesamtkaprendite: 3.56%

Eigenkaprendite: 5.84%

>EISAI Peer Group

Es sind 52 Aktien bekannt.

>EISAI Chart & Kurs - Tradegate

>EISAI News

27.10.25 - 03:57	Health Canada Grants Authorization for Leqembi® (lecanemab) (PR Newswire)
	STOCKHOLM, Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of......

14.10.25 - 09:33	First patient treated with Leqembi® (lecanemab) in the Nordics (PR Newswire)
	STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the......

14.10.25 - 07:21	Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 (PR Newswire)
	STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the......

14.10.25 - 07:18	Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 (PR Newswire)
	STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the......

14.10.25 - 01:33	LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME′s "Best Inventions of 2025" (PR Newswire)
	TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI® IQLIK™, a subcutaneous......

14.10.25 - 01:33

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME′s “Best Inventions of 2025” (GlobeNewswire EN)

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category....

07.10.25 - 03:48	Eisai And Biogen: LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer′s Treatment (AFX)
	WESTON (dpa-AFX) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for maintenance......

07.10.25 - 00:09	Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. (PR Newswire)
	STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's......

07.10.25 - 00:03	Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. (PR Newswire)
	STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's......

06.10.25 - 22:36	Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer′s Disease (PR Newswire)
	New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more LEQEMBI IQLIK, approved by the U.S. FDA in August 2025,......

03.10.25 - 05:30	Erste Patienten bekommen Alzheimer-Mittel Lecanemab (DPA-AFX)
	BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten ......

02.10.25 - 14:12	Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 (PR Newswire)
	Multiple endometrial carcinoma abstracts to be presented, including long-term follow-up data for lenvatinib plus pembrolizumab in advanced disease from Study 309/KEYNOTE-775 Final bone metastases subgroup analysis from pivotal Phase 3 CLEAR study in advanced renal cell carcinoma among......

01.10.25 - 09:06	AKTIONÄR-Hot-Stock BioArctic: Nächste Zulassungen (Der Aktionaer)
	Das neuartige Alzheimer-Medikament Leqembi (Lecanemab) steht immer mehr Menschen rund um den Globus zur Verfügung. Fortan darf das Mittel auch in Australien und in einer weiteren Darreichungsform in China von der japanischen Eisai und dem US-Biotech-Konzern Biogen vertrieben werden....

29.09.25 - 08:42	Leqembi® approved for IV maintenance treatment in China (PR Newswire)
	STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National......

29.09.25 - 08:39	Leqembi® approved for IV maintenance treatment in China (PR Newswire)
	STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National......

29.09.25 - 03:30	Eisai: LEQEMBI Approved In China For Monthly IV Maintenance Dosing In Early Alzheimer′s Treatment (AFX)
	WESTON (dpa-AFX) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced that the National Medical Products Administration (NMPA) of China has approved LEQEMBI-a humanized ......

25.09.25 - 23:48	XFRA: DIVIDEND/INTEREST INFORMATION - 29.09.2025 - JP3160400002 (XETRA)
	Das Instrument EII JP3160400002 EISAI CO. LTD EQUITY wird cum Dividende/Zinsen gehandelt am 26.09.2025 und ex Dividende/Zinsen am 29.09.2025 The instrument EII JP3160400002 EISAI CO. LTD EQUITY has its pre-dividend/interest day on 26.09.2025 and its ex-dividend/interest day on 29.09.2025...

24.09.25 - 13:33

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer′s Disease in Australia (GlobeNewswire EN)

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers....

23.09.25 - 02:12	Eisai Alzheimer′s drug Leqembi shows early signs of momentum shift - Bernstein (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.09.25 - 01:33	Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation (PR Newswire)
	TOKYO, Sept. 16, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die meisten freien Schriftsteller sind nur Nebenerwerbsschriftsteller. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram